SCYNEXIS INC — Director's Dealing 2014

May 2, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: SCYNEXIS INC (SCYX)
CIK: 0001178253
Period of Report: 2014-05-02

Reporting Person: FCPR Biotechnology Fund (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Common Stock Warrant (right to buy)	$0.20	2016-12-06	Common Stock (5251)		Direct
Common Stock Warrant (right to buy)	$0.20	2017-05-14	Common Stock (5251)		Direct
Common Stock Warrant (right to buy)	$0.20	2018-12-10	Common Stock (25998)		Direct
Series B Preferred Stock	$		Common Stock (46863)		Direct
Series C Preferred Stock	$		Common Stock (88796)		Direct
Series D-1 Preferred Stock	$		Common Stock (42336)		Direct
Series D-2 Preferred Stock	$		Common Stock (30582)		Direct

Footnotes

F1: Each of the Series B Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-3.536 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.

F2: Each of the Series C Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-3.536 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.

F3: Each of the Series D-1 Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-20.4 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.

F4: Each of the Series D-2 Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-20.4 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.